Genelux
Develops Olvi-Vec, an oncolytic virus therapy for platinum-resistant ovarian cancer.
$2.66
After-hours close−0.01 (−0.31%)
At close$2.67(−7.29%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions 20.74%9.30M sharesInsiders 7.31%3.28M sharesOther 71.95%32.26M shares
Shares outstanding 44.84M · Float 36.13M · 80.6% free float
Institutions13F, as of Mar 31, 2026
71 holders · 9.30M shares · 12 new positions · 27 increased · 15 reduced · 18 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Woodward Diversified Capital, LLC | 2.12M | 4.72% | +184.5K | Apr 24, 2026 |
| Vanguard Capital Management LLC | 1.70M | 3.78% | +1.70Mnew | May 15, 2026 |
| Bleichroeder LP | 1.38M | 3.08% | +666.7K | May 14, 2026 |
| Geode Capital Management, LLC | 453.8K | 1.01% | +72.4K | May 15, 2026 |
| BlackRock, Inc. | 405.9K | 0.91% | +20.6K | May 13, 2026 |
| Bank of America Corp /DE/ | 323.9K | 0.72% | −12.2K | May 18, 2026 |
| Flputnam Investment Management Co | 280.9K | 0.63% | −22.4K | May 5, 2026 |
| Vanguard Fiduciary Trust Co | 251.6K | 0.56% | +251.6Knew | May 8, 2026 |
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Armistice Capital, LLC | 9.99% | 4.22M | 13G | Nov 14, 2025 ↗ |
| Aladar Szalay | 8.20% | 3.13M | 13G | Feb 17, 2026 ↗ |
| Highbridge Capital Management, LLC | 6.80% | 2.50M | 13G | Oct 25, 2024 ↗ |
InsidersForm 4
| Insider | Role | Shares | % outstanding | Filed |
|---|---|---|---|---|
| Thomas Zindrick | officer: President and CEO | 1.26M | 2.81% | Aug 4, 2026 |
| John Thomas | director | 501.2K | 1.12% | Jun 18, 2026 |
| Joseph Cappello | officer: Chief Technical Officer | 328.7K | 0.73% | Aug 4, 2026 |
| Matthew Pulisic | officer: Chief Financial Officer | 278.9K | 0.62% | Jun 18, 2026 |
| Yong Yu | officer: Chief Scientific Officer | 268.4K | 0.60% | Aug 4, 2026 |
| Eric Groen | officer: General Counsel | 234.0K | 0.52% | Jun 18, 2026 |
| Mary Mirabelli | director | 102.7K | 0.23% | Jun 18, 2026 |
| James L. Tyree | director | 96.5K | 0.22% | Jun 18, 2026 |
| John W. Smither | director | 91.4K | 0.20% | Jul 2, 2026 |
| Ralph Smalling | officer: Head of Regulatory | 67.6K | 0.15% | Jun 4, 2026 |
1 ten-percent owner holds 599.8K shares by Form 4, outside the officers-and-directors figure above · 5 people have not refiled in the last 18 months (244.4K shares), so they are not in the figure above
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Aug 4, 2026 | Thomas Zindrickofficer: President and CEO | Sale | 3,023 | $2.95 | 1,260,890 |
| Aug 4, 2026 | Joseph Cappelloofficer: Chief Technical Officer | Sale | 653 | $2.95 | 328,737 |
| Aug 4, 2026 | Yong Yuofficer: Chief Scientific Officer | Sale | 653 | $2.94 | 268,371 |
| Jul 1, 2026 | John W. Smitherdirector | Sale | 12,000 | $2.91 | 91,403 |
| Jun 3, 2026 | Ralph Smallingofficer: Head of Regulatory | Sale | 192 | $2.93 | 67,611 |
| Jun 1, 2026 | John Thomasdirector | Sale | 10,000 | $2.98 | 472,784 |
| May 11, 2026 | Ralph Smallingofficer: Head of Regulatory | Sale | 270 | $2.98 | 67,803 |
| May 11, 2026 | Thomas Zindrickofficer: President and CEO | Sale | 2,798 | $2.94 | 532,051 |
| May 11, 2026 | Joseph Cappelloofficer: Chief Technical Officer | Sale | 605 | $2.97 | 154,549 |
| May 11, 2026 | Yong Yuofficer: Chief Scientific Officer | Sale | 605 | $2.97 | 149,706 |
CongressHouse and Senate disclosures
Not reported.